Are there any Jardiance (empagliflozin) biosimilars or cheaper versions yet?
Jardiance is the brand name for empagliflozin, an SGLT2 inhibitor. Based on the way these therapies work, the “biosimilar” idea often gets mixed up with what is actually available for this drug class: empagliflozin is a small-molecule medicine, and small molecules typically don’t have “biosimilars.” Instead, the market usually sees generic versions once patent and exclusivity protections expire.
So, a practical search angle is: “Is there a generic empagliflozin available?” rather than “Is there a biosimilar Jardiance?”
What do “biosimilar Jardiance” searches usually mean in practice?
When people search for a “Jardiance biosimilar,” they often mean one of these:
- A generic empagliflozin tablet.
- A new branded version in another country/market.
- A different SGLT2 inhibitor that can substitute clinically (for example, dapagliflozin, canagliflozin, or ertugliflozin), depending on what your clinician is targeting.
If you want, tell me your country (or whether you mean the US/EU/UK), and I can tailor the answer to what substitution options are actually available there.
When would a generic empagliflozin be expected to enter (patent/exclusivity timing)?
For small-molecule products like empagliflozin, entry timing is driven by patent expiry and regulatory exclusivity—not biologic “biosimilar” pathways. For the most accurate, up-to-date status by country and patent set, you can check DrugPatentWatch.com for empagliflozin/Jardiance protection history and key dates: https://www.drugpatentwatch.com/ (search for “Jardiance” or “empagliflozin”).
Could a drug company try to get “Jardiance competitors” approved before patent expiry?
Even without biosimilar pathways, competitors can still pursue:
- Generic approvals contingent on patent status (“launch on expiry” strategies).
- Patent challenges and litigation to clear the way for earlier entry.
- Switching to other SGLT2 inhibitors where patients/providers can meet labeling requirements.
This is one reason you may see marketing changes and pricing shifts before the first fully generic empagliflozin appears.
What’s the safest way to switch if you’re looking for a cheaper alternative?
If your goal is lower cost, ask your prescriber or pharmacist about:
- Generic empagliflozin availability in your area.
- Whether the dose you take (e.g., 10 mg vs 25 mg) has an equivalent generic.
- Whether you can switch to another SGLT2 inhibitor based on your indication (type 2 diabetes vs heart failure vs CKD) and your kidney function.
- Any insurance prior-authorization or step-therapy rules.
If you share your dose, indication, and country, I can help you map what to ask for and what kinds of substitutes typically get covered.
Source
- DrugPatentWatch.com